Highly-accurate metabolomic detection of early-stage ovarian cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gaul, David A ^a   Mezencev, Roman ^a   Long, Tran Q ^b   Jones, Christina M ^a   Benigno, Benedict B ^c   Gray, Alexander ^b   Fernández, Facundo M ^a   McDonald, John F ^a,c  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b Georgia Institute of Technology   (United States)

^c Ovarian Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; LYSOPHOSPHATIDYLETHANOLAMINE; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; TUMOR MARKER;

ADULT; AGED; BLOOD; CASE CONTROL STUDY; EARLY CANCER DIAGNOSIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; METABOLOME; METABOLOMICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PRINCIPAL COMPONENT ANALYSIS; SENSITIVITY AND SPECIFICITY; STANDARDS; SUPPORT VECTOR MACHINE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; BIOMARKERS, TUMOR; CA-125 ANTIGEN; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; METABOLOME; METABOLOMICS; MIDDLE AGED; OVARIAN NEOPLASMS; PRINCIPAL COMPONENT ANALYSIS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TANDEM MASS SPECTROMETRY;

EID: 84947465966     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16351     Document Type: Article

References (26)

1. Jelovac, D., & Armstrong, D. K. Recent progress in the diagnosis and treatment of ovarian cancers. CA. Cancer J. Clin. 61, 183-203 (2011).
2. Cancer Fact & Figures 2013. American Cancer Society, Atlanta, GA, USA (2013).
3. Munoz, K. A. Harlan, L. C., & Trimble, E. I. Patterns of care for women with ovarian cancer in the United States. J. Clin. Oncol. 15, 3408-3415 (1997).
4. Clark-Pearson, D. L. Screening for ovarian cancer. New Engl. J. Med. 361, 170-177 (2009).
5. Bosse, K., et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol.Oncol. 103, 1077-1082 (2006).
6. Menon, U., et al. Risk algorithm using serial biomarker measurements doubles the number of screen-detected cancers compared with a single-Dhreshold rule in the United Kingdom collaborative trial of ovarian cancer screening. J. Clin. Oncol. 33, 2062-71 (2015).
7. Elzek, M. A., & Rodland, K. D. Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev. 34, 83-96 (2015).
8. Zhen, H., Liu, J. Y., Song, F. J., & Chen K. X. Advances in circulating microRNAs as diagnostic and prognostic markers for ovarian cancer. Cancer Biol. Med. 10, 123-130 (2013).
9. Guan, W., et al. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinformatics. 10, 259-274 (2009).
10. Zang, X., et al. Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics. J. Proteome Res. 13, 3444-3454 (2014).
11. Rakotomamonjy, A. Variable selection using SVM-based criteria. J. Machine Learn. Res. 3, 1357-1370 (2003).
12. Pyragius, C. E., Fuller, M., Ricciardelli, C., & Oehler, M. K. Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer. Int. J. Mol. Sci. 14, 7742-7756 (2013).
13. Omabe, M. Ezeani, M., & Omabe, K. N. Lipid metabolism and cancer progression: the missing target in metastatic cancer treatment. J. App. Biomed. 13, 47-59 (2015).
14. Havrilesky, L., et al. Prognostic significance of p53 mutations and p53 overexpression in advanced epithelial ovarian cancer: a gynecological oncology group study. J. Clin. Oncol. 21, 3814-3825 (2003).
15. Hu, J., Liu, Z., & Wang, X. Does TP53 mutation promote ovarian cancer metastasis to omentum by regulating lipid metabolism? Med. Hyp. 81, 515-520 (2013).
16. Sutphen, R., et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 13, 1185-1191 (2004).
17. Pineiro, R., Maffucci, T., & Falasca, M. The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene 30, 142-152 (2011).
18. Vivanco, I., & Sawyers, C. L. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat. Rev. Can. 2, 489-501 (2002).
19. Fruman, D. A., & Rommel, C. PI3K and cancer: lessons, challenges and opportunities. Nat. Rev. Drug Disc. 13, 140-156 (2014).
20. Morad, S. A. F., & Cabot, M. C. Ceramide-orchestrated signaling in cancer cells. Nat. Rev. Can. 13, 51-65 (2013).
21. Zhou, M., et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Can. Epidemiol. Biomark. Prev. 19, 2262-2271 (2010).
22. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
23. Nguyen, L., et al. Biomarkers for early detection of ovarian cancer. Women's Health 9, 171-187 (2013).
24. Arakaki, A. K., Skolnick, J., & McDonald, J. F. Marker metabolites can be therapeutic targets as well. Nature 456, 443 (2008).
25. Fan, R. E., Chang, K. W., Hsieh, C. J., Wang, X. R., & Lin, C. J. LIBLINEAR: A library for large linear classification. J. Machine Learn. Res. 9, 1871-1874 (2008).
26. Sumner, L. W., et al. Proposed minimum reporting standards for chemical analysis chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomic 3, 211-221 (2007).